1. Patients with slow hepatitis B need long-term management First of all, patients with slow hepatitis B may lead to serious consequences if they do not receive long-term management. The current study results suggest that the incidence of hepatitis B-related liver cancer in western countries is about 20%, while in China, where HBV is highly endemic, hepatitis B infection is the main cause of liver cirrhosis and liver cancer, accounting for 60%-90%. As a person with chronic hepatitis B infection, he needs to receive long-term management in several areas: drug therapy, evaluation of drug therapy-related efficacy and detection of toxic side effects such as drug resistance, regular follow-up and lifestyle adjustment. For patients with chronic hepatitis B infection, long-term management is required whether they are in the immune tolerance (viral carriage) or immune clearance (active hepatitis) phase, or in the inactive or low-replication and re-replication phases. 3. The benefits of adhering to long-term effective management Patients with chronic hepatitis B can obtain long-term benefits as long as the following four key aspects are addressed Reasonable drug selection, timely medication, regular follow-up, and regular lifestyle. Hepatitis B infection in highly endemic areas is the main cause of cirrhosis and liver cancer occurrence accounting for 60-90%.